MétaCan
Menu
Back to cohort
Record W4288080559 · doi:10.1111/all.15456

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma

2022· article· en· W4288080559 on OpenAlexafffund
Alberto Papi, Jonathan Corren, Mario Castro, Christian Domingo, Linda Rogers, Kenneth R. Chapman, Daniel J. Jackson, Nadia Daizadeh, Nami Pandit‐Abid, Rebecca Gall, Juby A. Jacob‐Nara, Paul J. Rowe, Yamo Deniz, Benjamin Ortiz

Bibliographic record

VenueAllergy · 2022
Typearticle
Languageen
FieldMedicine
TopicAsthma and respiratory diseases
Canadian institutionsUniversity of Toronto
FundersCanadian Institutes of Health ResearchSanofi GenzymeGenentechGrifolsAstraZenecaChiesi FarmaceuticiCSL BehringRegeneron PharmaceuticalsTeva Pharmaceutical IndustriesPatient-Centered Outcomes Research InstituteNational Institutes of HealthAllergy TherapeuticsShionogiSanofiMereo BioPharmaVifor PharmaPfizerAmgen
KeywordsDupilumabMedicineLung functionAsthmaAsthma exacerbationsSeverity of illnessLungIntensive care medicineImmunologyInternal medicine

Abstract

fetched live from OpenAlex

Abstract Background Severe asthma exacerbations increase the risk of accelerated lung function decline. This analysis examined the effect of dupilumab on forced expiratory volume in 1 s (FEV 1 ) in patients with moderate‐to‐severe asthma and elevated type 2 biomarkers from phase 3 LIBERTY ASTHMA QUEST (NCT02414854). Methods Changes from baseline in pre‐ and post‐bronchodilator (BD) FEV 1 and 5‐item Asthma Control Questionnaire (ACQ‐5) scores were assessed in patients with elevated type 2 biomarkers at baseline (type 2–150/25: eosinophils ≥150 cells/μl and/or fractional exhaled nitric oxide [FeNO] ≥25 ppb; type 2–300/25: eosinophils ≥300 cells/μl and/or FeNO ≥25 ppb), stratified as exacerbators (≥1 severe exacerbation during the study) or non‐exacerbators. Results In exacerbators and non‐exacerbators, dupilumab increased pre‐BD FEV 1 by Week 2 vs placebo; differences were maintained to Week 52 (type 2–150/25: LS mean difference (LSMD) vs placebo: 0.17 L (95% CI: 0.10–0.24) and 0.17 L (0.12–0.23); type 2–300/25: 0.22 L (0.13–0.30) and 0.21 L (0.15–0.28)), in exacerbators and non‐exacerbators, respectively ( p < .0001). Similar trends were seen for post‐BD FEV 1 . Dupilumab vs placebo also showed significantly greater improvements in post‐BD FEV 1 0–42 days after first severe exacerbation in type 2–150/25 (LSMD vs placebo: 0.13 L [0.06–0.20]; p = .006) and type 2–300/25 (0.14 L [0.06–0.22]; p = .001) patients. ACQ‐5 improvements were greater with dupilumab vs placebo in both groups. Conclusion Dupilumab treatment led to improvements in lung function independent of exacerbations and appeared to reduce the impact of exacerbations on lung function in patients who experienced a severe exacerbation during the study.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.557
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.249
Teacher spread0.240 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations8
Published2022
Admission routes2
Has abstractyes

Explore more

Same venueAllergySame topicAsthma and respiratory diseasesFrench-language works237,207